MRNA - Moderna, Inc

Healthcare - Sector
Coverage Profile Rating Distribution Performance Price Targets & Ratings Chart

MRNA is currently covered by 16 analysts with average potential upside of $15.04 (18.54%) backed by 194 price targets and 277 ratings. Documented since 02-Jan-2019. Analyst's average stock valuation to be materialised ratio is 78.94% with an average time for price targets to be met of 68.91 days.

Most recent stock forecast was given by TYLER VAN BUREN from COWEN on 13-Mar-2023.

Highest price target for MRNA is 456, Lowest price target is 118, average price target is 287.

Moderna is a biotechnology company that focuses on the development of mRNA therapeutics and vaccines. The company was founded in 2010 by a group of scientists, including Derrick Rossi and Noubar Afeyan, with the aim of using mRNA to develop new therapies for a variety of diseases.

The company’s first major breakthrough came in 2017, when it developed a personalized cancer vaccine that uses mRNA to stimulate the immune system to attack cancer cells. This vaccine is currently in clinical trials and has shown promising results.

In December 2018, Moderna went public, raising $604 million in its initial public offering. The company’s stock has since skyrocketed, with a market capitalization of over $150 billion as of March 2022.

Moderna’s revenue has surged in recent years, driven by its COVID-19 vaccine. In 2021, the company reported revenue of $19.2 billion, up from just $60 million in 2019. The vast majority of this revenue came from sales of the COVID-19 vaccine, which has been authorized for emergency use in over 50 countries.

The COVID-19 pandemic has been a major driver of Moderna’s success. The company was one of the first to develop a vaccine for the virus, using its mRNA technology to create a vaccine that is highly effective and has a good safety profile. Moderna’s vaccine was authorized for emergency use by the US Food and Drug Administration in December 2020 and has since been used to vaccinate millions of people around the world.

In addition to its COVID-19 vaccine, Moderna has a robust pipeline of other mRNA therapeutics and vaccines in development. The company is working on treatments for a variety of diseases, including cancer, heart disease, and rare genetic disorders. Moderna is also developing vaccines for other infectious diseases, such as Zika and cytomegalovirus.

Headquartered in Cambridge Massachusetts, is a leading biotechnology company providing groundbreaking treatments and vaccines for the prevention of infectious diseases like COVID-19, flu, RSV and more. Additionally they offer innovative therapies to combat rare illnesses such as cytomegalovirus (CMV), HIV/AIDS; herpes simplex virus (HSV); varicella-zoster virus( VZV) infections; along with immuno oncology solutions to fight cardiovascular disease & auto immune disorders in USA , Europe & through out the world .

Moderna is leading the way in innovative solutions to disease, with therapeutics and vaccines for cancer treatments as well as localized regenerative, systemic intracellular, and inhaled pulmonary therapies. The company has forged strategic alliances with medical names such as AstraZeneca PLC, Merck & Co., Vertex Pharmaceuticals Incorporated and Carisma Therapeutics amongst others. To further its impact on global health initiatives Moderna also entered into collaboration agreements with Chiesi Farmaceutici SPA along side licenses from Defense Advanced Research Projects Agency (DARPA), Biomedical Advanced Research Development Authority (BARDA) Institute for Life Changing Medicines and even a partnership of The Bill & Melinda Gates Foundation.

In October 2022 Merck exercised an option to jointly develop and commercialize the treatment, known as mRNA-4157/V940, sharing costs and any profits equally. Merck and Moderna plan to discuss the results with regulatory authorities and start a large Phase III study in melanoma patients in 2023.

The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. They are designed to target highly mutated tumors.



Currently, out of the existing stock ratings of MRNA - 70 which are a Buy (50%), 55 which are a Hold (39.29%), 15 which are a Sell (10.71%)

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score



$33.08 (22.52%)


16 days ago

7/8 (87.5%)

$10.77 (10.16%)





$53.08 (36.13%)


1 months 1 days ago

5/6 (83.33%)

$9.98 (12.98%)





$-53.92 (-36.70%)


1 months 5 days ago

4/20 (20%)

$-65.45 (-40.67%)





$58.08 (39.53%)


2 months 5 days ago

27/34 (79.41%)

$29.44 (26.04%)





$61.08 (41.57%)


2 months 11 days ago

5/6 (83.33%)

$7.96 (6.91%)



Show more analysts

What is MRNA(Moderna, Inc) average time for price targets to be met?

On average it took 68.91 days on average for the stock forecasts to be realized with a an average price target met ratio 78.94

Which analyst has the current highest performing score on MRNA(Moderna, Inc) with a proven track record?